Aquinox – $75 Million Public Offering

Seattle – October 13, 2016 – Cooley advised Aquinox Pharmaceuticals on its $75.4 million public offering of 6,152,500 shares of common stock.

Aquinox, which trades on The NASDAQ Global Market as AQXP, is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology.

Cooley advised Aquinox on its IPO in 2014 and its follow-on offering in 2015. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Michael Tenta Partner, Palo Alto
Chadwick Mills Partner, San Francisco
Natasha Leskovsek Partner, Washington, DC
Bill Christiansen Partner, Seattle
Mark Windfeld-Hansen Partner, Palo Alto
Francis Wheeler Partner, Colorado
Alan Hambelton Partner, Seattle
Julia Stark Associate, Seattle